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Workshops are an important part of the IFPA annual meeting as they allow for discussion of specialized
topics. At IFPA meeting 2016 there were twelve themed workshops, four of which are summarized in this
report. These workshops covered innovative technologies applied to new and traditional areas of
placental research: 1) genomic communication; 2) bioinformatics; 3) trophoblast biology and pathology;
4) placental transport systems.
© 2017 IFPA and Elsevier Ltd. All rights reserved.
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Chair: Yoel Sadovsky.
Speakers: Larry Chamley, Peter Kurre, Nathan Price, Alison
Paquette, and Carlos Salomon.
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1.1. Outline
While circulating RNAs, either bound by plasma proteins or
packaged within extracellular vesicles (EVs), may transmit information to researchers about tissue function, disease, and organismal wellness, recent data indicate that these messages play a key
role in local and distant cell communication. Using a series of targeted and provocative exchanges, this workshop centered on the
transfer of RNAs within EVs and their entry into target cells, the use
of minimally invasive, circulating RNA biomarkers for disease
monitoring, and the integration of these data into longitudinal
assessment of pregnancy health, projecting a futuristic view of
“scientiﬁc wellness.”
1.2. Summary
Larry Chamley discussed the role of RNAs in syncytial nuclear
aggregates/trophoblast debris in fetal control of maternal physiology. The syncytiotrophoblast layer of the human placenta extrudes a wide variety of EVs into the maternal blood, ranging in size
from multinucleated syncytial nuclear aggregates (SNAs) and other
trophoblast debris, to nano-vesicles. Dr. Chamley's group found
that SNAs/trophoblast debris contain multiple RNA species
including fragments from mRNA, snRNA, piRNA and tRNA, as well
as intact mature miRNA. When SNAs/trophoblast debris from
normal ﬁrst trimester placentae were incubated with endothelial
cells, the endothelial cells substantially altered their transcriptome
and expressed placenta-speciﬁc genes, such as chorionic gonadotropin and placental lactogen, and their angiogenic capacity was
increased. Such changes may be important for normal maternal
physiological adaptations to pregnancy. Small RNA species in SNAs/
trophoblast debris signiﬁcantly differ between normal and preeclamptic placentae. The ﬁnding that functional miRNAs could be
delivered to endothelial cells via SNAs/trophoblast debris, suggests
that changes in the miRNA cargo of SNAs/trophoblast debris may, in
part, be responsible for the inappropriate endothelial cell responses
in preeclamptic pregnancies.
Peter Kurre discussed evidence that EVs contribute to intercellular genomic communication using the crosstalk between leukemia cells and hematopoietic stem cells as a paradigm. His work
illustrated key concepts of vesicle-mediated transfer of RNA in
phenotypically regulating diverse cell populations in the bone
marrow compartment by EV-transferred miRNA. The studies
revealed both paracrine and endocrine trafﬁcking of EVs. The presentation highlighted approaches to the study of transfer and
regulation, and identiﬁed opportunities for EVs as a platform for
miRNA biomarkers.
Nathan Price outlined a strategy to leverage genomic and other
data for optimizing personal wellness. Two fundamental challenges
to pregnancy research are: 1) a general paucity of longitudinal
molecular data; 2) difﬁculties in developing potential therapies due
to the sensitive nature of launching clinical trials during pregnancy.
Recently, Lee Hood and Dr. Price have completed a pilot study d the
Pioneer 100 d for a 100K wellness project. The aim of this project is
to build a discipline called “scientiﬁc wellness.” Dense, dynamic,
personal data clouds will be created for each individual, including
their whole genome sequence as a baseline, adding repeated
measurements of clinical chemistries, metabolites, proteomes,
microbiomes, and data from wearables, over time. These data will
be interrogated to identify actionable possibilities for individuals to
help optimize wellness and reduce disease risk. Dr. Price discussed
how such an approach could result in valuable, dense longitudinal
data for the ﬁeld and provide a low-risk strategy for improving
pregnancy outcomes, such as pre-term birth.
Alison Paquette discussed genome-scale analysis of miRNA

regulation in preterm labor (PTL). Dr. Paquette's group performed
global miRNA and mRNA proﬁling in both monocytes and whole
blood of women who experienced preterm labor (N ¼ 15) matched
to non-pathological controls (N ¼ 30), as a part of the Ontario Birth
Cohort. They identiﬁed differentially expressed miRNAs, mRNAs
and pathways associated with preterm labor using differential rank
conservation (DIRAC). They identiﬁed 34 miRNAs associated with
preterm labor in whole blood and monocytes. When comparing
these data to an independent dataset of non-pathological pregnancies (N ¼ 25), they found that many miRNAs differentially
expressed in PTL, were expressed in the placenta. miR-1299
expression, associated with PTL, was correlated between placenta
and maternal plasma. This comprehensive proﬁling of miRNA and
mRNA regulation identiﬁed speciﬁc biomarkers of preterm labor.
Carlos Salomon discussed optimizing methods to isolate and
quantify placenta-derived exosomes from maternal circulation. Dr.
Salomon's group has optimized methods to speciﬁcally isolate and
quantify circulating placental exosomes in maternal circulation,
using antibody-based enrichment of exosomes on magnetic beads
and by Nanoparticle Tracking Analysis (NanoSight™) using quantum dots (Qdots) coupled with CD63 or placental alkaline phosphatase (PLAP) antibodies. They have validated the speciﬁc binding
of PLAP-beads or PLAP-Qdots using exosomes isolated from syncytiotrophoblast (positive control) and plasma from non-pregnant
women (negative control). They determined that ~12% and ~20%
of the total circulating exosomes are from placental origin in early
gestation (i.e. ~10e12 weeks) and third trimester (i.e. >32 weeks),
respectively. These methods may help proﬁle and characterize
exosomes from placental origin under normal and pathological
conditions.
1.3. Conclusions
Observations discussed at this workshop suggest a central role
for exosomes and syncytiotrophoblastic aggregates in inﬂuencing
the biology of target tissues during pregnancy as well as during the
process of carcinogenesis (such as leukemia). The use of vesicular
circulating RNA biomarkers (mainly microRNAs) for disease
monitoring, and the integration of these data into longitudinal
assessment of pregnancy health, projects a futuristic view of “scientiﬁc wellness”.
2. Bioinformatics and omics applied to the placenta
Chair: Lucia Carbone.
Speakers: Diana Morales-Prieto, Priyadarshini Pantham, Katie
Powell, Geetu Tuteja, Samantha Wilson.
2.1. Outline
Rapid advances in omics technologies and associated bioinformatics tools have signiﬁcantly inﬂuenced the placenta ﬁeld. One of
the ultimate goals of performing omics analyses is the identiﬁcation
of biomarkers that reﬂect the status of the placenta, the mother and
the baby. Bioinformatics analysis and integration of such datasets,
however, present many challenges. Firstly, references for placental
transcriptomes, metabolomes, and epigenomes are missing, hindering the interpretation and integration of omics data. Secondly,
the range of variability within the population is still unknown, thus,
a baseline to evaluate adverse proﬁles is missing. During this
workshop, scientists involved in the analyses of different types of
omics data (e.g. epigenomes, microRNAomes and metabolomes),
elaborated on the current methods used to obtain and analyze
omics data and strategies used to deal with the issues raised above.
Furthermore, some of the provocative questions raised in the
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placenta ﬁeld when omics data are generated and analyzed, are
beginning to be addressed.
2.2. Summary
Diana Maria Morales-Prieto presented data on the expression
of Chromosome 14 miRNA cluster (C19MC) and C14MC miRNAs and
their potential involvement in pregnancy disorders. Inappropriate
vessel transformation by trophoblast cells is associated with preeclampsia (PE) and intrauterine growth restriction (IUGR), while
exacerbated trophoblast invasion occurs in placenta accreta. Human trophoblast cells express two large miRNA clusters: C14MC
and C19MC. These miRNAs regulate human pregnancy by controlling trophoblast cell functions, including cell proliferation and invasion. miRNAs in these clusters were differentially expressed
between normal and pathological placentas. For instance, miR-370
was upregulated in placenta accreta, and down-regulated in earlyonset PE compared to controls. miRNAs from the same cluster had
similar expression proﬁles suggesting dysregulation of entire
families. C19MC and C14MC miRNAs could potentially be useful for
molecular classiﬁcation of pregnancy pathologies, but this will
require further study.
Priyadarshini Pantham reported on the identiﬁcation of a core
placental transcriptome across 14 different species of placental
mammals spanning the phylogenetic tree. The mRNA environment
of the placenta was quantiﬁed using RNA-seq technology, and 1:1
Homo sapiens orthologs were identiﬁed. The core placental transcriptome was signiﬁcantly enriched for pathways involved in
epidermal growth factor receptor (EGFR) signaling. Study limitations included the inability to collect placental samples from all
species throughout gestation, cellular heterogeneity, and animals
without reference transcriptomes. The core placental transcriptome described may be critical for the organization and
function of the placenta across these species.
Katie Powell discussed the use of metabolomics to identify
novel predictive biomarkers of pregnancy complications. She
described aspects of study design, including analysis of samples
using nuclear magnetic resonance (NMR) spectroscopy, and
methods for data analysis. Advantages of this technology include
the high degree of accuracy and precision in the measurement of
multiple metabolites from a sample, high sample throughput, and
low processing cost. Field limitations include the reduced sensitivity of low abundance metabolites via NMR spectroscopy and the
low number of published validation studies conﬁrming the role of
individual metabolites identiﬁed in discovery studies. Metabolomics has the capacity to identify new biomarkers that will increase our understanding of disease processes and these
biomarkers have the potential to be developed into clinical
screening tests.
Geetu Tuteja presented challenges in ChIP-Seq data analysis,
and strategies to overcome them. Although ChIP-Seq is becoming a
routine method, best practices in experimental design and data
analysis are often overlooked. ChIP-Seq requires multiple biological
replicates and control data to obtain meaningful results. Read
quality should be assessed and, if necessary, reads should be
trimmed prior to sequence alignment. Software, used to identify
protein-DNA interactions from ChIP-Seq data (peak-callers), were
shown to give widely different results from the same input data,
signiﬁcantly affecting downstream analysis. Therefore, peak-callers
should be chosen carefully, and parameters should be understood
and set prior to running analyses.
Samantha Wilson discussed the potential of using placental
epigenetic changes as biomarkers. The placenta shows a pattern of
DNA methylation (DNAm) that is unique compared to other tissues.
Fetal sex, gestational age, ethnicity, and cell type are important
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factors that inﬂuence placental DNAm. Thus, a change in placental
DNAm may represent: 1) an active modiﬁcation in DNAm within a
cell type; or 2) a change in proportion of different cell types between placentas. For a placental-speciﬁc epigenetic biomarker to
be usable, it cannot be masked by DNAm signatures from maternal
tissues, and should display sufﬁciently large changes in DNAm for
detectability. To reﬂect protein expression, the methylated site
must regulate gene expression, encode a protein, and the protein
must be shed into the maternal circulation in large enough
amounts to be detected. In the future, omics data must be integrated to achieve a better understanding of how all of these pieces
interact with each other.
2.3. Conclusions
The discussions during and after this workshop centered on the
use of OMICS for studying the placenta and the difﬁculties that
scientists are currently experiencing. Although generating data is
becoming common practice in many laboratories, the analysis still
weighs on investigators. Analysts that have expertise to mine the
data often lack an understanding of the biology and the complex
questions that need to be addressed. Establishing a solid and lasting
partnership between these two sides will be key to make sure that
all useful information are obtained from the omics data.
3. Trophoblast biology & pathology
Chair: Shawn L. Chavez and Julie C. Baker.
Speakers: Shawn L. Chavez, Roberta L. Hannibal, Louise C. Laurent, Balaji M. Rao.
3.1. Outline
Normal placental development is largely dependent upon the
differentiation and invasion of the trophoblast, which originates
from the trophectoderm of the blastocyst prior to embryo implantation. Given that aberrant trophoblast development is a
common phenomenon observed in pregnancy complications such
as preterm labor, preeclampsia, and IUGR, much research emphasis
is placed on the genetic, epigenetic, and chromosomal aspects
regulating trophoblast function. Recent technological advances in
genome-wide DNA methylation analysis and next generation
sequencing (NGS), as well as the use of human pluripotent stem
cells to assess trophoblast regulation, has provided considerable
insight into normal placental development and the pathophysiology of these pregnancy-related diseases. The objectives of this
workshop were to discuss NGS and other emerging approaches for
assessing trophoblast competency at the single-cell and/or wholegenome level. We also discussed how this work has provided novel
diagnostics to understand and predict placental misregulation.
Lastly, we reviewed key trophoblast regulators, including endogenous retroviruses, and intracellular signaling pathways mediating
trophoblast fate that are important for normal placental function.
3.2. Summary
Shawn L. Chavez discussed the role of endogenous retroviruses
(ERVs) in primate placentation. Although initially classiﬁed as
“junk” DNA, several ERVs were found to maintain coding potential
and play important biological roles in mammalian development.
While ERV-W (Syncytin-1) and ERV-FRD (Syncytin-2) are important for normal trophoblast syncytialization, the precise function of
ERV-K, the most recently acquired ERV in the human genome, remains unknown. Dr. Chavez highlighted previous reports of ERV-K
mRNA and certain retroviral protein components in normal human
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placental tissues and discussed similar observations of single-cell
ERV-K expression in rhesus monkey embryos and placentas. She
also reported on the expression and potential function of ERV-K in a
primate maternal infection model with or without antibiotic therapy. Her data suggests that ERV-K is active at the maternal-fetal
interface and has a distinct role in normal human and nonhuman primate placental development.
Louise C. Laurent presented genomic approaches her lab has
used to identify novel regulatory factors involved in trophoblast
differentiation. In the ﬁrst approach, microarray-based gene
expression data from a broad range of tissue and cell types were
analyzed to identify placenta and cytotrophoblast-speciﬁc transcripts. One such transcript was Grainyhead-like protein 1 homolog
(GRHL1) and is the focus of ongoing functional analyses, using
in vitro differentiation of human embryonic stem cells as a model
system. Dr. Laurent also presented proof-of-concept for a single-cell
transcriptomics approach to build regulatory networks associated
with a stepwise differentiation system, using human embryonic
stem cell differentiation to the pancreatic lineage as the test model.
Roberta L. Hannibal reported on trophoblast misregulation in
placenta accreta. In accreta, the placenta abnormally invades
uterine tissues. While prior uterine surgery is a risk factor, suggesting a uterine component, previous histopathology has also
found defects in trophoblast cells. Dr. Hannibal sequenced multiple
regions of placentas with and without accreta. She found genes
upregulated in the entire placenta of accreta cases. These genes are
enriched for previously unidentiﬁed secreted and membrane
molecules she has termed Accreta (ACC) #1e4. Their overexpression was conﬁrmed using semi-quantitative immunoﬂuorescence. To examine whether these upregulated proteins could be
used as potential biomarkers for accreta, they will be measured in
maternal plasma. Overall, this data suggests that uterine damage
does indeed lead to trophoblast misregulation.
Balaji M. Rao discussed pluripotent stem cell models of human
placental development. Trophoblasts derived from human pluripotent stem cells (hPSCs) are a promising in vitro model system for
studying early trophoblast development. However, a consensus
must be reached as to which markers should be used to conﬁrm
that hPSC-derived trophoblast subtypes are similar to trophoblasts
in vivo. Dr. Rao's group determined that the expression of certain
DNA methyltransferases and chromatin remodeling genes is largely
consistent between trophoblasts produced in vitro and in vivo. They
also demonstrated that hypomethylation of the E74-Like ETS
Transcription Factor-2b promoter and down-regulation of human
leukocyte antigen class I antigens, is observed in hPSC-induced
trophoblasts. This suggests that in vitro-derived trophoblasts
possess similar properties as their in vivo counterparts.
3.3. Conclusions
Despite the ethical, legal, and technical challenges of studying
early human placental development, recent advances in single-cell
and/or whole-genome analyses as well as the use of hPSC-derived
trophoblasts has provided considerable insight into the regulation
of trophoblast differentiation. With ongoing and future efforts, the
precise molecular mechanisms mediating normal trophoblast
function, and how it is disrupted across pregnancy-associated diseases, may be elucidated.
4. Transport NextGen: cool new stuff
Chair: Nick Illsley.
Speakers: Christiane Albrecht; Cassidy Blundell; Che-Ying Kao;
Charles McKenzie.

4.1. Outline
This workshop looked at several new technologies that are
becoming available for research into placental transport and provide new opportunities for investigation.
4.2. Summary
Christiane Albrecht introduced the successful establishment of
a conﬂuent human primary trophoblast monolayer using Matrigelcoated Transwell® inserts. During 5-day culture, trophoblasts
showed polarization exhibiting a modest transepithelial electrical
resistance (>1.2 kU$cm2) and a size-dependent apparent permeability coefﬁcient. The syncytialization progress was characterized
by gradually increasing levels of fusogen genes and hCG secretion.
Electron microscopy conﬁrmed a conﬂuent trophoblast monolayer
with numerous microvilli and tight junctions. Immunocytochemistry showed positivity for the cell-cell adhesion molecule E-cadherin, and the tight junction protein ZO-1 between mononucleated
cytotrophoblasts. Studying the bidirectional transport of a nonmetabolizable glucose derivative in presence of the inhibitor
phloretin indicated a carrier-mediated placental glucose transport
mechanism with asymmetric kinetics. Development of this model
opens the way for integrated studies of trans-syncytial transport
and the analysis of its complex mechanisms and kinetics.
Cassidy Blundell presented work on the development and
characterization of the placenta-on-a-chip, a microengineered
model that reconstitutes the bilayer structure of the human
placental barrier. This system enables compartmentalized coculture of trophoblast and endothelial cells in a dynamic ﬂow
environment. Preliminary studies of glucose transport were performed and the rate of maternal-to-fetal glucose transfer in the
placenta-on-a-chip matched rates measured in an ex vivo placental
perfusion model. This work illustrates the potential for leveraging
this microphysiological platform for studying placental transport.
Che-Ying Kuo discussed engineering diffusion of chemoattractants in bioprinted tissues. The development of a chemotactic
gradient plays a critical role in regulating trophoblast invasion that,
if not properly regulated, can lead to preeclampsia. Dr. Kuo's group
has recently leveraged the advantages of bioprinting (e.g. spatial
control of biomaterials) and created a novel Bioprinted Placenta
Model with a chemotactic gradient to study trophoblast migration.
In this workshop, Dr. Kuo presented methods used to establish the
chemotactic gradient, including 3D Bioprinting, time-lapse ﬂuorescent imaging and mathematical modeling. This method may be
extended to study other transport phenomena during trophoblast
invasion, such as cell migration and invasion.
Charles McKenzie presented prospects for non-invasive measurement of placental metabolic and transport processes with
Hyperpolarized Magnetic Resonance Imaging (MRI). Hyperpolarised MRI of 13C labeled substrates is an emerging new technology for imaging placental metabolism and transport in vivo. This
technology images the distribution of molecules, such as [1e13C]
pyruvate, in real time, allowing the dynamics of metabolism and
transport to be investigated without the use of invasive techniques
that could disturb placental physiology. Importantly, this technique
uses stable, non-radioactive isotopes so it is safe to use repeatedly,
allowing investigation of changes in metabolism and transport
across gestation. It also has the potential for use in humans, making
in vivo metabolism and transport processes in the human placenta
observable for the ﬁrst time.
4.3. Conclusions
The new techniques described in this workshop have promise
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for revolutionizing studies of transport. These models present the
possibility, for the ﬁrst time, of analyzing transport in complex
structures, beyond the previous “black-box” approach, which
characterizes methods such as lobule perfusion. The ability to track
objects, from metabolites up to cellular size, in multicellular systems will signiﬁcantly advance the ﬁelds of transport and

metabolism and provide even greater translational relevance.
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